Market Research Report
Pricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under Pressure
|Published by||GBI Research||Product code||238357|
|Published||Content info||99 Pages
|Pricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under Pressure|
|Published: April 20, 2012||Content info: 99 Pages||
This publication has been discontinued on February 2, 2017.
GBI Research, the leading business intelligence provider, has released its latest research "Pricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under Pressure". The report provides a comprehensive overview of the healthcare expenditure, healthcare regulatory system, and pricing and reimbursement process with key data, information and analysis of pricing and reimbursement decisions, across 19 countries. The report closely scrutinizes the major changes in generic drugs-related pricing and reimbursement in the 19 countries over recent years and whose impact will be felt in the near future. It also describes the efforts taken by the governing bodies in shaping the pricing and reimbursement policies of generic drugs.
GBI Research has found that expenditure towards healthcare has shown an increasing trend in most of the countries due to rising costs, resulting in budget deficits. In order to save costs, many countries have adopted reference pricing as it helps lower drug costs. Plans to increase generic drug prescription and low-cost generic drug use are being implemented in order to tackle budget deficits. Austerity measures that include price cuts and rebate reforms have been introduced in some of the countries with a view to generate maximum savings within a given period of time. These steps are being taken to build sufficient funds for future investment purposes. In most countries the focus has shifted to generic drugs as they have been successful in bringing these countries out of crisis; the countries have reformed their pricing and reimbursement structure accordingly.